Abstract Body

In May 2018 a preliminary safety signal for neural tube defects among women on dolutegravir (DTG) at conception led to in-country guidance for individualized counseling for pregnant women who had already conceived on DTG and women on DTG or starting antiretroviral treatment (ART) who desired pregnancy; DTG-based ART otherwise remained the recommended regimen for new ART starts. We evaluated patterns of DTG use before and after this guidance.

This is a secondary analysis of data abstracted from Aug 2016-Sept 2019 in the Tsepamo birth outcomes surveillance study. HIV diagnosis date, ART regimens taken before or during pregnancy and dates of ART initiation and discontinuation were collected from all women living with HIV who delivered at study sites. Botswana national HIV treatment guidelines recommended DTG-based ART from May 2016 onward, with updated guidance related to pregnancy intention issued in May 2018.

Among 20,254 women living with HIV who delivered from Aug 15, 2016-Aug31, 2019, 13,205 (65.2%) were on ART prior to conception, 5,718 (28.2%) started ART during pregnancy, 904 (4.5%) received no ART and 427 (2.1%) had unknown timing of ART start. The proportion of deliveries with DTG conception exposure increased steadily during the study period to a maximum of 30% in 10/2018 (Figure 1a). Among women who likely conceived in the 5 months after the May 2018 guidance, 27% of conceptions were on DTG-based ART, which was unchanged from 28% in the 5 months prior to the guidance. Before May 2018, 97% of women initiating ART in pregnancy started DTG-based ART (1.7% <6 weeks gestational age)(Figure 1b). After May 2018, only 43% of starts in pregnancy were DTG-based ART (1.6% <6 weeks gestational age), and 56% started EFV-based ART. Among 441 who changed ARVs during pregnancy, 177 (40%) switched from DTG-based ART to EFV-based ART (99% after May 2018). Only 71 (0.4%) women completely discontinued ART during pregnancy, including 35 women on DTG and 24 on EFV.

Program guidance based on individual counselling regarding pregnancy intention had no apparent impact on the number of women who conceived on DTG-based ART in 2018-2019 in Botswana. However, pregnant women frequently initiated non-DTG-based ART, or switched off DTG-based ART, despite being beyond the NTD risk period. Evaluation of clinician and patient perceptions of the NTD risk, and improvement in understanding pregnancy intention and barriers to pregnancy planning, will be critical for developing treatment guidelines within DTG-based ART programs.